kdigo controversies conference novel techniques and ... › wp-content › uploads › 2017 › 02...

33
Monitoring the Hemodialysis Dose KDIGO Controversies Conference Novel techniques and innovation in blood purification: How can we improve clinical outcomes in hemodialysis? October 14-15, 2011 Paris France Monitoring the Hemodialysis Dose Tom Depner, M.D. University of California, Davis

Upload: others

Post on 31-Jan-2021

0 views

Category:

Documents


0 download

TRANSCRIPT

  • Monitoring the Hemodialysis Dose

    KDIGO Controversies ConferenceNovel techniques and innovation in blood purification:

    How can we improve clinical outcomes in hemodialysis?October 14-15, 2011

    Paris France

    Monitoring the Hemodialysis Dose

    Tom Depner, M.D.University of California, Davis

  • © 2001 By Default!Slide 2

    Removal of accumulated smallsolutes is important

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    solutes is important

  • How long will I live if I choose to stop dialysis?

    This varies from person to person. People who stop dialysis may live anywhere from who stop dialysis may live anywhere from one week to several weeks, depending on the amount of kidney function they have leftand their overall medical condition.

    National Kidney Foundation web site

  • Art Buchwald

    Famous as a syndicated humorist in life, after his death he is more notable for his reputation as the man who beat hospice and the kidney machine.

  • How long will I live if I choose to stop dialysis?

    The median time to death after stopping The median time to death after stopping dialysis in a series of 18 patients reported by Rich was 7 days (0-17 days)

    Rich A, Palliative Med 15:513-14, 2001.

  • The cause of death is uremia

    � Principal cause: accumulation of toxic solutes normally excreted by the kidney

    � Evidence: dialysis works by removing small solutes.solutes.

    � Death is not due to anemia, vitamin D deficiency, hyperparathyroidism, fluid overload, accumulation of beta 2-microglobulin, etc, etc.

  • Minimum urea clearance for Hemodialysis

    KDOQI guidelines call for a continuous equivalent Kt/Vurea of 2.0 volumes/week.

    2.0 volumes per week x 35 L = 70 L/week

    = 70,000 ml/L /10080 min/week

    = 7 ml/min

  • © 2001 By Default!Slide 8

    HEMO Study: Survival by Kt/V Group

    A Free sample background from www.pptbackgrounds.fsnet.co.ukEknoyan et al, N Eng J Med 2002

  • 3

    4

    5

    6

    7

    We

    ek

    ly D

    ialy

    sis

    Do

    se

    (s

    tdK

    t/V

    )

    6

    Hemodialysissessions/wk

    HEMO: High

    DailyDialysis

    Effect of Increasing Number of Effect of Increasing Number of Effect of Increasing Number of Effect of Increasing Number of Dialysis Sessions Per WeekDialysis Sessions Per WeekDialysis Sessions Per WeekDialysis Sessions Per Week

    9

    0.0 0.5 1.0 1.50

    1

    2

    3

    We

    ek

    ly D

    ialy

    sis

    Do

    se

    (s

    tdK

    t/V

    )

    3

    HEMO: Standard

    Dialysis dose each dialysis (eKT/V)

    7 ml/min

    8 ml/min

  • Slide 10

    Deficiencies of Kt/V

    � Residual kidney function not considered

    � Solute disequilibrium is under-represented

    No provision for dialysis frequency� No provision for dialysis frequency

    � K and t may not be equivalent

    � V is independently associated with outcome

    � Non-linear correlation with outcome

  • Effect of Kr-urea on mortality in HD patients

    12

    14

    16

    18

    20

    RR

    mo

    rta

    lity

    5.0 to 62.6

    Adjustments: age, Adjustments: age, comorbidity score, comorbidity score, primary kidney primary kidney disease, SGA, BMIdisease, SGA, BMI

    Termorshuizen F, et al: JASN 15:1061Termorshuizen F, et al: JASN 15:1061--70, 200470, 2004

    0

    2

    4

    6

    8

    10

    RR

    mo

    rta

    lity

    0 0 to 0.84 >0.84

    KrT/V per week

    reference1.1 to 2.6

  • Slide 12

    Deficiencies of Kt/V

    � Residual kidney function not considered

    � Solute disequilibrium is under-represented

    No provision for dialysis frequency� No provision for dialysis frequency

    � K and t may not be equivalent

    � V is independently associated with outcome

    � Non-linear correlation with outcome

  • Slide 15

    Standard K (and Kt/V) - Gotch

    continuous removal rate

    average peak concentrationStandard K =

    In a steady state, the removal rate is equal to the generation rate (G)

    Standard K =G

    average peak concentration

  • © 2001 By Default!Slide 16

    Standard Kt/V

    t

    e110080

    Kt/V

    eKt/V−

    =

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    1Nt

    10080

    eKt/V

    e1tKt/V

    eKt/Vstd

    −+−

    =−

    Gotch, FA: Nephrol Dial Transplant 13 Suppl 6:10-14, 1998

    Leypoldt, JK: Seminars In Dialysis 17:142-145, 2004

  • © 2001 By Default!Slide 17

    Standard Kt/V adjusted for Uf and Kru

    stdKt/V = S/[1 - (0.74/F) • Uf/V]

    + Kru • [0.974/(spKt/V + 1.62) + 0.4] • 10/V

    A Free sample background from www.pptbackgrounds.fsnet.co.ukDaugirdas J, et al: Kidney Int 2010

    S is the unadjusted stdKt/V per week

    F is the number of dialyses/week

    Uf is the weekly fluid removal in liters

    Kru is the residual native kidney clearance of urea in ml/min

    spKt/V is the single pool Kt/V per dialysis

    V is the urea distribution volume in liters

  • 4.0

    5.0

    6.0

    7.0S

    tandard

    Kt/

    VContinuous vs. intermittent clearance expressions

    7/week

    6

    5

    4

    per

    week

    0.00 0.50 1.00 1.50 2.00 2.50

    spKt/V per dialysis

    0.0

    1.0

    2.0

    3.0

    Sta

    ndard

    Kt/

    V

    3

    2

    1

    per

    week

  • © 2001 By Default!Slide 19

    4.0

    5.0

    6.0

    7.0R

    e-d

    efin

    ed

    Kt/

    V (

    pe

    r w

    ee

    k)

    Continuous versus peak concentration methods

    Mean methodPeak method

    7/week

    6

    5

    4

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    0.00 0.50 1.00 1.50 2.00 2.50

    spKt/V per dialysis

    0.0

    1.0

    2.0

    3.0

    Re

    -de

    fin

    ed

    Kt/

    V (

    pe

    r w

    ee

    k)

    3

    2

    1

  • Slide 20

    Deficiencies of Kt/V

    � Residual kidney function not considered

    � Solute disequilibrium is under-represented

    No provision for dialysis frequency� No provision for dialysis frequency

    � K and t may not be equivalent

    � V is independently associated with outcome

    � Non-linear correlation with outcome

  • © 2001 By Default!Slide 21

    0.90

    1.00

    1.10

    1.20K

    t/V

    Effect of treatment time on eKt/V

    eKt/V1.09

    spKt/V

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    2 4 6 8 10

    Td (treatment time in hours)

    0.60

    0.70

    0.80

    0.90

    Kt/V

    0.87

  • Treatment time predicts mortalitySaran et al from DOPPS, Kid Int 69:1222-28, 2006

    New NKF-KDOQI Hemodialysis Guidelines

  • © 2001 By Default!Slide 23

    1.20

    1.40

    Rela

    tive R

    isk o

    f death

    Mortality and Body Mass IndexUSRDS: 3607 patients enrolled in CMAS, Jan 1991

    ad

    juste

    d f

    or

    ag

    e,

    se

    x,

    race

    & o

    the

    r fa

    cto

    rs

    quintile means ñ 95% confidence intervals

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    15 20 25 30 35 40 45

    BMI

    0.80

    1.00

    Rela

    tive R

    isk o

    f death

    Source: Leavey et al, AJKD 31:1002, 1998

    ad

    juste

    d f

    or

    ag

    e,

    se

    x,

    race

    & o

    the

    r fa

    cto

    rs

  • © 2001 By Default!Slide 24

    Kurea•t

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    urea

    Vurea

  • © 2001 By Default!Slide 25

    Continuous risk (hazard) plane for Ktand BSA. The analysis did not include an inter-action term between Kt and BSA and was case mix adjusted.

    43,334 patients

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    Continuous risk (hazard) plane for Ktand BSA. The analysis included an interactionterm between Kt and BMI and was case mixadjusted.

    Lowrie E, et al: KI 62:1891-7, 2002

  • Slide 26

    Deficiencies of Kt/V

    � Residual kidney function not considered

    � Solute disequilibrium is under-represented

    No provision for dialysis frequency� No provision for dialysis frequency

    � K and t may not be equivalent

    � V is independently associated with outcome

    � Non-linear correlation with outcome

  • 0.6

    0.8

    1.0R

    esponse (

    R)

    Concentration (Dose) - Response CurveHill equation: applies to a direct reversible effect

    (1/Q) + CSCS

    R =

    0.5 1.0 10.0

    Concentration (C in arbitrary units)

    0.0

    0.2

    0.4

    Response (

    R)

  • 6.0

    8.0

    10.0C

    on

    ce

    ntr

    atio

    n (

    C in

    arb

    itra

    ry u

    nits) Concentration versus Clearance

    C = 1/K

    0.0 0.2 0.4 0.6 0.8 1.0

    Clearance (K) in arbitrary units)

    0.0

    2.0

    4.0

    Co

    nce

    ntr

    atio

    n (

    C in

    arb

    itra

    ry u

    nits)

  • 2

    2.5

    3

    3.5

    4

    4.5

    5

    0

    0.5

    1

    1.5

    2

    0 5 10 15 20

    Steady-state solute concentration

  • Some proposed improvements to Kt/V

    • Include residual native kidney clearance (Kr)

    • Account for solute disequilibrium» eKt/V

    • Allow for more frequent dialysis» Standardized Kt/V

    • Index to surface area instead of V

    • Tighter correlation with outcome» reciprocal of Kt/V

  • © 2001 By Default!Slide 31

    Summary: uremia is a complex state

    Comorbidity (DM, CVD, nutrition, anemia, etc)Comorbidity (DM, CVD, nutrition, anemia, etc)

    Residual Syndrome:Residual Syndrome:

    Slowly accumulating solutes:Slowly accumulating solutes:•• B2B2--microglobulin & other peptidesmicroglobulin & other peptides•• Calcium & phosphate depositsCalcium & phosphate deposits•• ProteinProtein--bound toxins?bound toxins?

    Comorbidity (DM, CVD, nutrition, anemia, etc)

    Residual Syndrome:

    Slowly accumulating solutes:• B2-microglobulin & other peptides• Calcium & phosphate deposits• Protein-bound toxins?

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    Life threatening toxins

    •• ProteinProtein--bound toxins?bound toxins?•• AGE’s ?AGE’s ?•• Carbamylated proteins ?Carbamylated proteins ?

    Toxic effect of dialysis Toxic effect of dialysis -- exposure to exposure to membrane, hemodynamic effectsmembrane, hemodynamic effects

    • Protein-bound toxins?• AGE’s ?• Carbamylated proteins ?

    Toxic effect of dialysis - exposure to membrane, hemodynamic effects

  • © 2001 By Default!Slide 32

    Future of dose monitoring

    Because control of small solute concentrations

    must be the principal goal of replacement

    therapy, future efforts should focus not on

    A Free sample background from www.pptbackgrounds.fsnet.co.uk

    therapy, future efforts should focus not on

    whether we should measure small solute

    clearance, but what else we should measure

    and do for our patients.

  • Adequacy of Dialysis

    = Removal of Toxins

    = Prevention of Uremia= Prevention of Uremia

    = Restoration of Health